PMID: 11913044Mar 27, 2002Paper

20/20 hindsight. Months after anthrax claimed the lives of several. Americans, hospitals review their reaction to the event--and plan for future crises

Modern Healthcare
Cinda Becker

Abstract

Last fall, after a nation suffered the unthinkable attacks of Sept. 11, a second wave of terror held Americans in its grip. Questions still surround a series of baffling cases of anthrax that shook New York and Connecticut. Each of the hospitals involved report that despite the unsolved mysteries posed by these events, they are more cautious and better-prepared for future bioterrorism attacks.

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.